Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive save search
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: -3.93%
covid-19 vaccine positive trial results
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
Published: 2024-03-26 (Crawled : 11:00) - globenewswire.com
PRAX | $46.88 0.62% 0.62% 350K
|
Health Technology
|
| O: 19.9%
H: 11.0%
C: 2.69%
prax-628 precision positive photo response results study
Quadient - Solid FY 2023 results bring the Back to Growth strategic plan to a close with Quadient well positioned for long-term profitable growth
Published: 2024-03-25 (Crawled : 17:00) - globenewswire.com
PAYD | News | $1.61 -25.0% 100
|
Information
|
| O: -100.0%
H: NaN%
C: Infinity%
back profitable results growth
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
Published: 2024-03-25 (Crawled : 14:00) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 5.18%
H: 0.0%
C: -12.5%
mb-106 positive aml trial
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
Published: 2024-03-25 (Crawled : 14:00) - biospace.com/
ATXS | $9.745 -7.54% -8.16% 1.2M
|
Manufacturing
|
| O: 10.71%
H: 0.9%
C: -11.94%
star-0215 positive trial therapeutics results
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
Published: 2024-03-25 (Crawled : 13:30) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.14%
H: 3.12%
C: 2.93%
positive meeting cardiology
Scripps nominates consumer research and data expert to company board position
Published: 2024-03-25 (Crawled : 13:00) - prnewswire.com
SSP | $3.59 4.06% 3.9% 740K
|
Consumer Services
|
| O: 0.72%
H: 10.86%
C: 8.86%
company research
DEEP GREEN Completes Asset Sale of Georgia Subsidiary and Strengthens Company Cash Position
Published: 2024-03-25 (Crawled : 12:30) - globenewswire.com
DGWR | $0.1199 -98.05% 190
|
Manufacturing
|
| O: 38.16%
H: 0.0%
C: -25.81%
company
Zscaler Positioned as Leader in New Tier 1 Analyst Firm Security Service Edge Research Report
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
ZS | $169.23 -2.16% -2.21% 2.3M
|
Technology Services
|
| O: -0.06%
H: 0.48%
C: -0.4%
report service security research
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
MTNB | $0.1877 -1.21% 0.0% 330K
|
Health Technology
|
| O: 15.11%
H: 0.0%
C: -9.31%
positive biopharma
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
Published: 2024-03-22 (Crawled : 15:30) - globenewswire.com
ESPR | $1.94 3.74% 3.61% 7.3M
|
Health Technology
|
| O: 0.0%
H: 13.74%
C: 8.53%
chmp positive hypercholesterolemia cardiovascular
Summit Midstream Partners, LP Announces Sale of Utica Position for $625 Million
Published: 2024-03-22 (Crawled : 12:30) - prnewswire.com
SMLP G | $27.76 -0.18% 0.0% 27K
|
Utilities
|
| O: 32.73%
H: 5.66%
C: 4.69%
MPLX | $40.68 1.17% 0.0% 3.7M
|
Industrial Services
|
| O: 0.02%
H: 0.05%
C: -0.27%
million
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-03-22 (Crawled : 12:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: -0.54%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 2.26%
H: 0.0%
C: -2.65%
chmp positive cancer treatment
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
OTLK P | $8.15 -1.69% -1.72% 270K
|
Health Technology
|
| O: 52.98%
H: 8.82%
C: -19.87%
ons-5010 therapeutics chmp positive treatment
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.17%
H: 0.28%
C: -0.01%
fabhalta first chmp positive novartis
Global OTC Artificial Tears Analysis Report 2023-2030: The Influence of Smart Technologies, Market Positioned for Continued Expansion Amid Growing Focus on Eye Wellness
Published: 2024-03-21 (Crawled : 00:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.17%
H: 0.28%
C: -0.01%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: -0.74%
H: 1.54%
C: 1.38%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
report expansion global wellness smart growing eye market
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
Published: 2024-03-21 (Crawled : 20:00) - biospace.com/
LUCD | $0.7941 -0.61% -0.62% 120K
|
|
| O: -0.9%
H: 8.18%
C: 0.91%
PAVM | $1.95 -1.03% 20K
|
Health Technology
|
| O: 0.45%
H: 5.41%
C: -4.5%
esoguard first positive diagnostics study
Lightbridge Senior Executives Assume Key Positions in Prestigious Nuclear Energy Industry Groups
Published: 2024-03-21 (Crawled : 12:00) - globenewswire.com
LTBR | $2.54 1.6% 1.57% 34K
|
Commercial Services
|
| O: 2.65%
H: 1.41%
C: -4.52%
energy nuclear key
LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
Published: 2024-03-20 (Crawled : 19:00) - biospace.com/
LIVN | $52.31 -0.85% -0.86% 430K
|
Health Technology
|
| O: 1.81%
H: 11.57%
C: 10.5%
success positive trial study
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
Published: 2024-03-20 (Crawled : 13:00) - biospace.com/
PBYI | $5.01 0.4% 0.4% 290K
|
Health Technology
|
| O: 2.33%
H: 7.73%
C: 6.7%
fda breast cancer hormone
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.